Press release: Manufacturing of life-enhancing medicines boosted by new government funding

first_imgOne year on from the launch of the Industrial Strategy, this £7.3 million investment is the latest commitment from the £180 million Industrial Strategy Challenge Fund (ISCF) dedicated to leading-edge Medicines Manufacturing.Taking steps to improve patient access to life-saving treatments and medicines, Advanced Therapy Treatment Centres, working across the UK, will support the roll-out of cell and gene therapies as clinical trials show them to be safe and cost-effective. The centres bring together expert clinicians, researchers, scientists, developers and private companies to demonstrate how the therapies have impact on patients’ lives.Advanced therapies, including cell and gene therapies, represent the next generation of therapies that have the potential to offer treatments for a number of conditions including some blood cancers and inherited conditions for which there are currently limited treatment options.UK Research and Innovation (UKRI) is responsible for managing the Industrial Strategy Challenge Fund, which funds the winners of the Medicines Manufacturing Challenge.Dr Ian Campbell, Interim Executive Chair, Innovate UK for UKRI, said: The 3 individual projects are: Arc Trinova in Northumberland will use new technologies to speed up the process of the production of patient specific medicines; it is currently a timely process dispensing individual doses from bulk because of the careful handling, labelling and batch release processes Oxford Biomedica will look to dramatically reduce the supply time for manufacturing by using a new digital and robotics framework to increase capacity, reduce waste and cut costs Autolus Ltd in London will look to avoid mix-ups of complex medicines on the supply chain by developing a computer based system that will constantly monitor the operation, making adjustments to timing, coordination and production where necessary, improving the efficiency of the whole system and working at a pace that human operators cannot imitate New technology can help us live longer, healthier lives and the new projects announced today will improve the speed and accuracy with which medicines get to the people that need them. Advances in technology can help us address the challenges that an ageing society presents and we are backing the technologies of tomorrow in our modern Industrial Strategy, with the biggest increase in public research and development investment in UK history. Autolus Ltd in London ‘Digital Delivery of Personalised Advanced Therapies’ that will look at using technology to boost the flawless tracking and tracing of thousands of individual patient batches to ensure there are no mix-ups ARC Trinova Ltd in Northumberland ‘Fill-Inova: Enabling flexible and agile highly potent medicines manufacture’ that will use technologies to increase the throughput to thousands of units per hour Oxford Biomedica ‘Digitalisation of Medicines Manufacturing’ that will look at how to dramatically reduce the supply time for manufacturing The projects announced today will bring real benefits to patients and boost the knowledge economy as part of the government’s modern Industrial Strategy. This is vital for the UK as a global leader in the development of advanced therapies and medicine manufacturing. The Cell and Gene Therapy Catapult is playing a key role in the coordinating the work of the 3 Advanced Therapy Treatment Centres to ensure that learning and best practice is shared effectively. They will allow the creation of bespoke manufacturing and supply systems capable of operating across the entire NHS with the potential to treat many patients each month.center_img 2 new programmes to help companies produce more medicines and get them to patients quicker have been given a multi-million pound government boost companies in Northumberland, Oxford and London have been awarded £4.3 million funding to develop digital solutions, including artificial intelligence, which will streamline production of next-generation medicines in a separate series of investments, delivering on the commitment made in the Life Sciences Sector Deal, a further £3 million has been awarded to support the work of Advanced Therapy Treatment Centres in rolling out new cell and gene therapies across the NHS Patients could soon receive faster treatment thanks to a multi-million pound government boost to streamline the production of medicines and treatments, including those used to treat blood cancers and inherited disorders.Companies in Northumberland, Oxford and London will adopt new digital technologies, such as artificial intelligence, to support the manufacture of next-generation medicines and treatments.The £4.3 million funding aims to create more efficient and innovative methods for manufacturing medicines. The challenge works to set the UK apart as a leader with greater capacity for manufacture of safe, affordable and effective therapies.Life Sciences Minister Lord Henley said: Innovate Manchester Advanced Therapy Centre Hub (iMATCH), The Midlands-Wales Advanced Therapy Treatment Centre (MW-ATTC, comprising Birmingham, Wales and Nottingham) The Northern Alliance Advanced Therapies Treatment Centre (NAATTC, comprising Scotland, Newcastle and Leeds) The Advanced Therapy Treatment Centres have been established previously by £21 million funding from the Industrial Strategy Challenge Fund and are working to develop systems and methodologies that will allow the delivery of advanced therapies across the healthcare system.The Advanced Therapy Treatment Centres are: Notes for editorsThe projects awarded funding in the Digitalisation of Medicines Manufacturing are:last_img read more

Odell Beckham Jr. speaks as if trade from Giants to Browns was his choice

first_imgConsidering the perceived trajectories of the Giants and Browns, there is no reason to dismiss Odell Beckham Jr. when the 26-year-old wide receiver suggests that, football-wise, he is in a better situation in Cleveland for 2019 than he would have been in New York.But while Beckham talks up his new team this summer, the NFL’s annual, league-wide period of unapologetic optimism, the awkward reality is that the superstar wideout did not choose to play for the Browns. He was traded. Of course, we all know how this works in the NFL: If the Browns win in 2019, any potential Beckham-related issues will be buried by the elation of success. And to Beckham’s point, Cleveland has a chance to compete for a playoff berth. New York, it seems, does not.But don’t let Beckham’s words mince the truth about his relocation to Cleveland. He was traded to the Browns; he did not sign with them in free agency.Because if things go poorly in Cleveland this season, chances are we’ll all be reminded. MORE: Browns-Steelers suddenly among the NFL’s best rivalriesIn a recent, wide-ranging interview with Complex UK, Beckham was asked about his “biggest career move to date.” His answer was just as conveniently void of the word “trade.””I just felt with the Giants I was just stuck at a place that wasn’t working for me anymore,” Beckham said. “I felt like I wasn’t going to be able to reach my full potential there; mentally, physically, spiritually, everything I felt capable of doing, I just couldn’t see it happening there. So I think allowing me to be in an environment where I can be myself and give it a different approach, I feel like my football will benefit.”I’m just excited about being able to play football again and not have to deal with all the other stuff and politics that came with my previous role.”Understandable? Certainly. Disingenuous? A little.This isn’t the first time — and it certainly won’t be the last — that Beckham has expressed his excitement about playing in Cleveland. He said he felt “like a little kid” during minicamp. He also recently told GQ about his unhappiness in New York.But Beckham did not ask to be traded by the Giants. And despite trade rumors that surfaced prior to the deal, New York general manager Dave Gettleman had said he wouldn’t move the wide receiver.”(Gettleman) said he wasn’t going to trade (Beckham), then he traded him,” Landon Collins — who also was traded away from New York this year — recently said of the Giants GM. “We (were) all surprised because that’s one of the best receivers in the game and for him to do that and lie to everybody, it’s not a good look for players and teammates.”To be fair, even though the Giants gave Beckham a massive contract extension late last summer, the 2019 season was rocky enough to have ruined any good feelings. The receiver was fined for his comments about quarterback Eli Manning’s play. He headbutted an AC unit on the Giants’ sideline during a blowout loss to the Eagles. He faced criticism from team owner John Mara. He was blamed for a failed onside kick recovery. He missed the last four games of the season with a quad injury.Yet even with that as the background, after the deal that sent Beckham to Cleveland, Browns quarterback Baker Mayfield had to respond to speculation that the wide receiver was unhappy with the trade. Sporting News contributor and former NFL team exec Jeff Diamond pointed to Beckham’s absence from the Browns’ voluntary OTAs as a sign he might not be as excited as he claims.MORE: Ranking the NFL’s top wide receivers for 2019last_img read more